Skip to main content


Anticipated launches and uptake of biosimilars are predicted to increase spending to $129 billion and savings by $180 billion over the next 5 years, according to a report by IQVIA. Read More ›

Results of a recent survey of cancer centers revealed that 66% of responding institutions had a biosimilar interchangeability policy in place, but barriers to adoption remain an issue. Read More ›

Standardizing biosimilar adoption in oncology through the electronic health record can improve biosimilar utilization and reduce health system costs. Read More ›

On September 21, 2022, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›

Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution. Read More ›

The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020. Read More ›

A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar. Read More ›

On May 23, 2022, the Association for Accessible Medicines (AAM) and its Biosimilars Council urged the Federal Trade Commission (FTC) to investigate the competitive impact of pharmacy benefit managers (PBMs) and their various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care. Read More ›

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table. Read More ›

The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC. Read More ›

Page 1 of 8